Logout

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Logout

Property Description
Active ingredient Allopurinol (INN)
Form Tablet (Oral dosage form)
Pharmacological class Xanthine oxidase inhibitor (XOI)
General purpose Uric acid reduction
Origin Synthetic drug

What is Logout and What Type of Medicine Is It?

Logout is a synthetic drug classified as a systemic agent used for the long-term management of conditions linked to high levels of uric acid in the body. Its core component is the active substance Allopurinol, the International Nonproprietary Name (INN) for the compound, which is administered as an oral dosage form, specifically a tablet.

As a single-ingredient product, the formulation consists of active Allopurinol combined with inert pharmaceutical excipients to create the final compressed unit. This preparation is a prescription-only medicine (Rx). Allopurinol is considered an essential medicine for the management of hyperuricemia, a status that reflects its established role in foundational health systems and clinical practice worldwide.

Logout’s Pharmacological Class: What Is a Uricostatic Agent?

Logout belongs to the broad class of antihyperuricemic agents and is technically defined as a xanthine oxidase inhibitor (XOI), a specific type of enzyme inhibitor. This function places the drug in the uricostatic agent category, as its primary action is to inhibit or stabilize the biochemical processes that create uric acid. This classification is clinically recognized for its role in modifying disease progression.

What Is the General Purpose of Logout?

The general purpose of using Logout is the control of high circulating levels of uric acid in the bloodstream, providing a critical preventative strategy against associated complications. Allopurinol acts by reducing the production of uric acid. By consistently lowering and stabilizing the concentration of uric acid, the medication helps prevent the hyper-saturation of bodily fluids and the subsequent deposition of urate crystals. Therefore, the benefit of Logout is central to the long-term management of conditions requiring the maintenance of low uric acid concentrations.

Regulatory References

  1. WHO Essential Medicines List (EML)
  2. Allopurinol in WHO EML
  3. EMA Medicines List

What side effects are possible with Logout?

Possible Side Effects and Safety Information

The safety profile of Logout, containing Allopurinol, is documented by government regulatory agencies based on frequency and impact on organ systems. The most common adverse reaction listed in regulatory documents is a skin rash, which is categorized under Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions

Despite the overall profile, the medicine is officially associated with rare but potentially fatal serious cutaneous adverse reactions (SCARs). These include Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Other serious events documented in regulatory labeling include Hepatitis (liver injury) and serious Blood and Lymphatic System Disorders such as Agranulocytosis (Myelosuppression).

Frequency and System Involvement

Adverse effects are classified according to regulatory frequency standards (e.g., Common, Uncommon, Rare). Gastrointestinal disorders (e.g., nausea, vomiting, diarrhea) and abnormal liver function tests are typically classified as Uncommon. Rare effects often involve the Hepatobiliary and Renal and Urinary Systems (e.g., renal failure).

Specific Safety Patterns and Risk Groups

Regulatory safety notes indicate that an increase in acute attacks of gout (Gout Flares) may be observed at the initiation of treatment, a time-related safety pattern. The risk of developing SCARs is higher in patients with pre-existing renal impairment and in individuals carrying the *HLA-B^58:01 gene allele. Official labeling requires immediate discontinuation of the medicine at the first appearance of a skin rash** or any other sign of hypersensitivity.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdose with Logout (Allopurinol) is officially documented to involve an exaggeration of adverse effects, including gastrointestinal symptoms such as nausea, vomiting, and diarrhea. The primary documented risks are severe systemic and organ toxicities. These include acute kidney failure (nephrotoxicity), acute liver failure (hepatotoxicity), and bone marrow depression. The most severe outcomes are associated with Allopurinol Hypersensitivity Syndrome (AHS), which may manifest as life-threatening Severe Cutaneous Adverse Reactions (SCARs), specifically Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS. Worsening renal function and certain genetic factors are noted in official labeling as factors that increase the risk of these severe outcomes.

When to Seek Immediate Medical Help

Regulatory guidance mandates that patients must seek immediate medical attention or call emergency services in the event of a known or suspected overdose. Furthermore, the medicine must be discontinued immediately upon the very first appearance of any signs indicative of an allergic reaction or severe skin reaction, such as a rash, fever, or painful, blistering skin. Treatment for overdose is symptomatic and supportive, as no specific pharmacologic antidote is known. Official instructions require continuous monitoring of both liver and renal function in these severe scenarios.

Therapeutic Uses of Logout

What Logout Is Used For: Main Therapeutic Applications

Logout (a brand name for the generic medicine eszopiclone) is a medication applied in addressing symptoms that interfere with daily functioning, commonly used across conditions presenting with acute episodes. Its core therapeutic domain is the management of insomnia in adults. It is used in situations involving recurrent or episodic manifestations, relevant in contexts involving heightened systemic burden.

The medicine is commonly used for managing conditions characterized by periods of heightened symptoms related to sleep. Its use is associated with easing symptoms that interfere with the process of falling asleep and staying asleep, which are often linked to organ-specific functional stress.

This supportive relief assists with maintaining functional stability and helps patients cope more steadily with symptom fluctuations. The general benefit is that it contributes to easing the overall symptom load during difficult episodes.

“Used in settings marked by temporary physiological imbalance, this support is relevant when supportive symptom management is appropriate.”

It is a medication that may assist with symptoms that create noticeable functional strain, and this approach is commonly used when symptoms intensify and supportive relief is needed.


Quick Fact: Relief for Symptoms that interfere with daily functioning

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility to use Logout (Allopurinol) is strictly defined by regulatory documentation, outlining populations who can and cannot receive the medicine. The medication is contraindicated and must not be used by any patient with a documented history of severe allergic reaction or hypersensitivity to Allopurinol or any excipients.

Age and Condition Rules

Eligibility is restricted by age: it is approved for adults for chronic hyperuricemia and gout, but use in pediatric patients is severely limited. For children, it is typically indicated only for hyperuricemia related to malignancy or specific inherited enzyme disorders; safety and efficacy for common adult uses are not established in those under 18 years. Use is officially restricted for individuals with impaired renal function or hepatic impairment due to the need for careful consideration.

Population-Specific Limitations

The medicine is not recommended for the treatment of asymptomatic hyperuricemia. Regulatory bodies also advise caution for patients who carry the *HLA-B58:01 allele. Furthermore, the official labeling advises against use during pregnancy (stating it may cause fetal harm) and lactation**.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Logout (Eszopiclone) is defined by pharmacokinetic and pharmacodynamic interactions. Pharmacokinetic modifications primarily involve the CYP3A4 metabolic pathway. Co-administration with potent CYP3A4 inhibitors, such as Ketoconazole, is a clinically significant interaction because it reduces the drug's clearance and results in a documented 2.2-fold increase in Logout exposure. Conversely, strong CYP3A4 inducers like Rifampicin are expected to decrease the drug's plasma levels and overall effect.

The pharmacodynamic domain involves substances that are Central Nervous System (CNS) depressants, including alcohol and medicinal product categories like opioids, benzodiazepines, and antipsychotics. Co-use with these agents results in additive CNS-depressant effects that are noted in regulatory information.

Formal restrictions exist for specific combinations. The co-administration of Oxybate forms (Sodium, Calcium, Magnesium, or Potassium Oxybate) is a formal contraindication due to pharmacodynamic synergism. Furthermore, a population-specific restriction means the use of potent CYP3A4 inhibitors is contraindicated in patients 65 years of age or older. A documented timing-based rule requires that the medication must not be taken with or immediately after a heavy, high-fat meal, as this food-drug interaction reduces the rate and extent of absorption.

Mechanism of Action

Logout (Allopurinol) functions as a specific enzyme inhibitor to inhibit the body's metabolic production of uric acid. Its mechanism involves a precise molecular cascade that results in reduced systemic plasma concentration of uric acid.

Targeted Blockade of the Uric Acid Synthesis Pathway

This domain covers the drug's interaction with the enzyme Xanthine Oxidase (XO), the key biological target. The medication acts as a false substrate, and in the process of being metabolized by XO, it produces Oxypurinol, a long-acting, stable inhibitor. This process effectively blocks the final two steps of the purine catabolism pathway: the conversion of Hypoxanthine ightarrow Xanthine and Xanthine ightarrow Uric Acid.

Sustained Inhibition and Systemic Metabolic Shift

This mechanism addresses the role of the long-lasting active metabolite, Oxypurinol. By binding tightly and persistently to the Xanthine Oxidase enzyme, it provides a sustained, systemic metabolic blockade. This prolonged inhibition leads to a key physiological change: it drastically reduces the overall production of Uric Acid while simultaneously elevating the concentration of its more soluble precursors, Hypoxanthine and Xanthine, that possess greater renal clearance compared to uric acid. This shift contributes to supporting the physiological state of reduced circulating Uric Acid concentration.

Dosage and Administration Information

How to Use Logout (Allopurinol): Official Administration Guidelines

Logout, which contains the active substance Allopurinol, is administered according to a specific, titrated regimen designed for the long-term management of hyperuricemia. The instructions for its use follow established clinical standards that define the route, dosing schedule, and required administration context.

Administration Scope

Instruction Detail
Route of Administration The primary route is Oral, using the tablet dosage form. An Intravenous (IV) Infusion route is available for the active substance for patients unable to take oral therapy.
Dosing Schedule Therapy begins with a low initial dose, typically 100 mg once daily. The dose is then slowly increased in increments of 100 mg at weekly intervals until the desired therapeutic level is achieved. The maximum recommended oral daily dose is generally 800 mg.
Timing and Frequency The tablet should be taken after meals to minimize gastrointestinal upset. It is generally administered once daily, but total daily doses exceeding 300 mg must be given in divided doses.
Dose Adjustment Reduced doses are mandatory for patients with renal impairment due to altered drug clearance, often starting at 100 mg per day or less and spaced out based on clearance rate.

Use Protocol and Constraints

The standard protocol requires continuous daily administration for long-term control. A procedural constraint dictates that treatment must not be initiated during an acute gout attack, as this can prolong the episode. Patients are also instructed to maintain adequate fluid intake throughout the course of treatment to ensure sufficient urinary output.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Logout (Allopurinol)


Evidence for Use in Chronic Gout and Hyperuricemia

Research has evaluated the use of Logout in adults with established gout and persistently high uric acid levels (hyperuricemia). These investigations include numerous Randomized Controlled Trials (RCTs) and larger studies that combine the information from multiple trials, known as systematic reviews and meta-analyses. Studies explored specific measurements of serum uric acid (SUA) concentration and monitored whether patients achieved specific target levels over defined time intervals. Research also monitored the frequency of gout flares (attacks) and the change in the size and number of tophi—the firm deposits of urate crystals—in populations where these were present. The reported data include measurements related to how SUA levels evolved in the observed populations, and the results apply only to the specific conditions and populations studied.


Evidence for Acute Prevention of Uric Acid Excess

Research was studied for a preventative role in specific, high-risk medical scenarios where the body produces a sudden, large amount of uric acid. One key area of research explored temporary physiological imbalance during chemotherapy for certain cancers, a condition known as Tumor Lysis Syndrome. Studies examined outcomes related to acute kidney injury in this setting, which is an outcome linked to systemic or functional imbalance. This approach was observed in research reviewed by major regulatory and clinical bodies for managing uric acid during certain chemotherapy protocols.


Understanding Long-Term Study Results and Durability

Clinical research on chronic conditions often includes long-term follow-up to assess sustained patterns. For Logout, studies monitored outcomes over periods ranging from one to over ten years. However, the long-term effects related to the durability of the measured outcomes are not fully established through highly controlled research settings. Follow-up durations were limited in some of the original definitive trials, and variability exists across observational studies.


Areas of Research and Uncertainty

Research has also gone beyond the medicine's primary role to explore its potential influence on cardiovascular and renal outcomes in populations that do not have gout. These studies monitored endpoints such as Major Adverse Cardiovascular Events (MACE) and changes in renal function markers. However, a key limitation is that the findings from large-scale RCTs have been mixed or have described inconsistent patterns when compared to extensive observational data; therefore, data supporting a role outside of the primary indication are uncertain. Research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. 2020 American College of Rheumatology Guideline for the Management of Gout
  2. Urate-lowering therapy for incident and recurrent gout: A systematic review and meta-analysis of randomized controlled trials

Frequently Asked Questions (FAQ)

Common questions about Logout (FAQ)


Q: How quickly can someone expect to feel the effect of Logout?

Regulatory documents state that the therapeutic effect begins relatively quickly, with a fall in serum and urinary uric acid levels typically starting within two to three days after treatment begins. However, it may require a week or more of consistent therapy for the full, intended effects of the medicine to be completely established.


Q: What happens if I forget to take Logout for a day?

Official patient guidelines provide a clear protocol for a missed dose. Official guidelines on a missed dose regimen may state that if the medicine is taken once a day, the missed dose can be taken upon remembering, unless it is close to the time for the next scheduled dose. In that case, the guidelines indicate that the missed dose should be skipped, and the patient should resume their usual schedule. Official sources state that doses should never be doubled.


Q: Are there any common foods or drinks that should be avoided when using Logout?

The drug is generally intended to be taken after a meal, which is a common recommendation to help prevent stomach upset. Regulatory patient information may suggest that avoiding particularly greasy or fatty foods is helpful if gastrointestinal issues are experienced while taking the medicine.


Q: I heard Logout can cause drowsiness. Is that a common side effect?

Official product information confirms that drowsiness is listed as a possible side effect of the medication. Regulatory warnings mention that if drowsiness occurs, activities requiring mental alertness, such as driving or operating complex machinery, should be avoided until an individual understands the effects of the medication.


Q: Does taking Logout mean I need to change my diet?

While on this long-term medication, official regulatory information advises patients to maintain an adequate fluid intake, such as water, to support the body's natural processes and ensure sufficient urinary output. Any broader fluid or diet modifications would require discussion with a healthcare professional.


Q: Can Logout interact negatively with popular pain relievers like ibuprofen?

Drug interaction reviewers generally do not note a direct interaction between the active substance in Logout and non-prescription pain relievers like ibuprofen (a non-steroidal anti-inflammatory drug or NSAID). It is noted in regulatory contexts that NSAIDs may be used for managing acute gout flares, particularly when beginning therapy.


Q: Is it true that Logout may interact with certain vitamins or supplements?

Official patient safety information indicates that there is often insufficient data available in clinical testing to confirm whether combining this medicine with various herbal remedies or supplements is safe. For any combination not explicitly listed in the drug label, consultation with a healthcare professional is necessary.


Q: Is Logout safe to use for older people (e.g., over 65)?

Logout is indicated for use in adults. Regulatory information notes that dose adjustments are often necessary for older adults, as kidney issues are common in this group and renal impairment mandates a reduced dose. Eligibility is ultimately determined by a healthcare provider based on the individual's specific health profile.


Q: Can someone with mild kidney issues use Logout?

Yes, regulatory guidelines address use in patients with reduced kidney function. The official dosage section mandates that patients with decreased renal function must receive a lower dose than those with normal function. The severity of the impairment is what determines the necessary adjustment to the dosage.


Q: Is Logout a new drug, or has it been around for a while?

The active ingredient in this medication, Allopurinol, has been in use for a long time, receiving its initial FDA approval in 1966. It is a foundational medicine and is officially recognized by the World Health Organization (WHO) as an essential medicine for the management of high uric acid.


Q: Why do official documents describe the drug's purpose in different ways?

The drug has several specific indications confirmed in regulatory documents, which leads to varied descriptions of its purpose. These indications include the long-term management of gouty arthritis and the prevention of a kidney condition called uric acid nephropathy, which can occur during certain chemotherapy protocols.


Q: Is it normal to feel a mild headache after starting Logout?

Official adverse reaction reporting includes general effects on the nervous system, and patient information sometimes lists headache as a possible side effect. If this symptom is severe, persistent, or causes concern, consultation with a healthcare professional would be necessary.


Q: Are there any signs that Logout might not be working for a person?

The key measurement used in clinical practice to check the medication's effectiveness is the serum uric acid (SUA) level, which is a blood test. Failure to consistently achieve the established target SUA level (typically 6 mg/dL or less) is the primary medical sign that the treatment may not be working at its current dose.


Q: What is the expected duration of effect after taking one dose of Logout?

The primary active component that controls uric acid, called oxipurinol, has a long half-life of approximately 15 hours. This sustained action is why the drug provides effective inhibition of uric acid production and manages levels over a full 24-hour period with a single daily dose.


Q: Does my weight or height influence how Logout affects me?

Official dosing for this drug is not based on a person's weight or height. Instead, the dose is adjusted based on the severity of the person's condition and is adjusted to achieve the desired therapeutic level of uric acid in the bloodstream.


Q: If I stop taking Logout, will my original condition immediately return?

The purpose of the medication is continuous, long-term management. Regulatory information notes that if therapy is stopped, uric acid levels may slowly return to the original high levels over a period of seven to ten days. Decisions regarding stopping or changing treatment should be guided by a healthcare professional.


Q: Does Logout have any known interactions with herbal teas or natural remedies?

Because herbal remedies and many supplements are not subjected to the same formal clinical testing as prescription medications, there is insufficient data in regulatory product information to confirm their safety when taken with this drug. Consultation with a healthcare provider is recommended regarding any combinations of this medicine with supplements or remedies.


Q: If Logout is used for a chronic condition, will it ever cure it?

The drug is indicated by official sources for the long-term management and reduction of uric acid levels in chronic conditions like gout. It is not described in regulatory documents as a cure, and it is usually taken continuously to control the underlying condition.


Q: Does Logout require any special laboratory tests or monitoring?

Yes, periodic monitoring is required to safely use this medication. Regulatory bodies recommend regular assessments of renal (kidney) function, liver function tests, and a complete blood count (CBC). Regular checks of the serum uric acid (SUA) level are also required to ensure treatment is meeting its goal.


Q: Is it possible to become dependent on Logout over time?

Regulatory information does not indicate a potential for dependence on this drug. However, because its purpose is long-term management and control of uric acid, the underlying condition can return if the medication is stopped, requiring continuous therapy to maintain the therapeutic benefit.

How should Logout be stored and disposed of?

How to Store and Dispose of Log-Out (Allopurinol)

The official labeling defines specific conditions for storing and disposing of Log-Out tablets to maintain product quality and safety.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature (20 C to 25 C / 68 F to 77 F). Do not allow the product to freeze.
Container Must be kept in the tightly closed container it came in.
Protection Store away from excess heat, moisture, and direct light.
Child Safety Must be kept out of the reach of children.

Disposal Instructions

Expired or unused Log-Out should not be kept. Disposal must follow procedures to prevent accidental ingestion and environmental contamination. The official recommendation is to utilize a drug take-back program or community collection site if available. If not, the tablets should be secured in a sealed container mixed with an undesirable substance, like cat litter, before being placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Logout found in:

A-Z Index: